Mark Throsby

Dr. Mark Throsby has spent more than 20 years in biotech. He gained a PhD in Immunology from Monash University Melbourne, Australia and spent four years as a research fellow with CNRS in Paris. Dr Throsby started his industry career at the formation of Crucell NV and worked for 8 years there in various roles finally as Director of Antibody discovery. He joined Merus NV in 2008 as CSO supporting the development of its bispecific antibody platform and leading preclinical research at the company until 2020. He joined Gadeta BV in 2020, a cell therapy company leveraging the unique targeting properties of the gamma delta TCR, and is currently serving as COO/CSO. He sits on the board of ONA Therapeutics Srl and is Executive Chairman of Alethiomics Ltd